Corvus Pharmaceu SEC Filings

Corvus Pharmaceuticals, Inc. Amendment No. 1 to a Schedule 13G/A reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen held 0% of the company's common stock as of the close of business on 03/31/2026. The cover page entries show zero voting and dispositive power for the reporting persons on that date.

Corvus Pharmaceuticals Schedule 13G: Sirenia Capital Management and Alex Silverstein report beneficial ownership of 6,831,828 shares of Common Stock issuable upon exercise of warrants, representing 7.5% of the class. This percentage is calculated using March 12, 2026 outstanding shares of 83,992,407 and assumes exercise of the warrants.

The filing states the shared voting and dispositive power over the 6,831,828 warrant-issuable shares and attaches a Joint Filing Agreement as Exhibit 99.1.

Corvus Pharmaceuticals reported final results from a randomized, blinded, placebo-controlled Phase 1 trial of oral ITK inhibitor soquelitinib in 72 patients with moderate-to-severe atopic dermatitis who had failed at least one prior topical or systemic therapy. Thirty-five percent had previously received systemic treatment, yet the drug showed dose-dependent efficacy and additional benefit with longer dosing. In the 200 mg twice-daily cohorts, 50% (cohort 3) and 75% (cohort 4) of patients reached EASI 75, with higher response rates in the longer 56-day cohort and durable disease control through 30–90 days of drug-free follow up without rebound or need for rescue medication. Safety appeared favorable, with adverse events in 41.7% of both soquelitinib and placebo groups, all Grade 1–2, no serious events, and no significant lab abnormalities. Extensive biomarker work suggested soquelitinib modulates Th2/Th17 pathways, increases persistent Treg cells, and affects JAK-STAT signaling, aligning with its proposed mechanism. Corvus is now enrolling a roughly 200-patient Phase 2 SIERRA1 trial in atopic dermatitis, while partner Angel Pharmaceuticals runs a parallel Phase 1b/2 study in China.

Corvus Pharmaceuticals reported a net loss of $13.7 million for the three months ended March 31, 2026, or $0.15 per basic and diluted share, compared with net income of $15.2 million a year earlier driven by a $25.1 million noncash gain from warrant revaluation. Operating expenses rose to $14.9 million as the company advanced its ITK inhibitor soquelitinib into a Phase 3 trial in relapsed peripheral T cell lymphoma and a Phase 2 trial in atopic dermatitis, and continued development of ciforadenant and mupadolimab. A January 2026 follow-on public offering of 9.1 million shares generated net proceeds of $189.4 million, lifting cash, cash equivalents and marketable securities to $236.7 million and extending the estimated cash runway into the second quarter of 2028.

Corvus Pharmaceuticals reported first quarter 2026 results and a major strengthening of its balance sheet while advancing its lead ITK inhibitor, soquelitinib. Cash, cash equivalents and marketable securities rose to $236.7 million as of March 31, 2026, including $189.4 million in net financing proceeds completed in January. Management believes this will fund operations into the second quarter of 2028.

R&D expenses increased to $11.2 million from $7.5 million a year earlier, mainly from higher soquelitinib clinical trial and personnel costs. The company posted a net loss of $13.7 million, versus net income of $15.2 million in 2025 that was driven by a large non-cash warrant liability revaluation.

Corvus initiated a Phase 2 atopic dermatitis trial for soquelitinib, continues a registrational Phase 3 trial in relapsed/refractory peripheral T cell lymphoma, and is preparing additional Phase 2 studies in hidradenitis suppurativa and asthma, highlighting a broader immune-disease strategy around ITK inhibition.

Corvus Pharmaceuticals director Andrew C. Chan received a grant of stock options for 30,000 shares of common stock. The options have an exercise price of $16.02 per share and expire on April 23, 2036. All 30,000 options were reported as directly owned following the grant.

The footnote explains that these options vest in three equal annual installments. One-third of the shares subject to the option will vest on each annual anniversary starting April 23, 2026, as long as Chan continues his service relationship with Corvus on each vesting date.

Corvus Pharmaceuticals, Inc. director Andrew C. Chan filed a Form 3, which is an initial statement of beneficial ownership for insiders. The filing lists him as a director and shows no reportable insider transactions, purchases, or sales at this time.

BlackRock, Inc. amends a Schedule 13G to report ownership of 5,387,818 shares of Corvus Pharmaceuticals common stock, representing 6.4% of the class. The filing shows sole voting power for 5,320,965 shares and sole dispositive power for 5,387,818 shares as reported on 04/27/2026.

The amendment cites aggregated holdings across BlackRock reporting business units and notes various clients/beneficiaries may have rights to dividends or proceeds. Exhibit references include a Power of Attorney and an Item 7 exhibit identifying relevant subsidiaries.

Corvus Pharmaceuticals, Inc. is holding a fully virtual annual meeting of stockholders on June 11, 2026 at 1:00 p.m. Pacific Time. Holders of 84,090,424 common shares as of April 16, 2026 can vote online, by phone or by mail on three main proposals.

Stockholders will vote on electing two Class I directors (Richard A. Miller and Linda S. Grais), ratifying PricewaterhouseCoopers LLP as independent auditor for 2026, and approving on a non-binding advisory basis the compensation of named executive officers. The board recommends votes in favor of all three proposals.